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A few years ago, I found myself in the
odd position of having to defend my work
to a mouse, actually a costumed Mickey
Mouse in Orlando after my daughter
gleefully informed him, “My daddy does
experiments on mice!” I tried to explain to
the shocked Mickey that our community
had identified countless epigenetic
changes in cancer, and that, while epige-
netics might explain part, or half, or most
of this horrible disease, nobody else
would believe it until we could recapitu-
late epigenetic changes in a model
organism. Had Mickey not run back to his
hole in the wall, I would have added that
this was a particularly acute problem
because epigenetic changes do not
involve DNA sequence variation, but her-
itable alterations such as methylation
that are pliable under certain conditions,
and thus potentially secondary and not
causal to the tumor process. Further,
while genes epigenetically activated or
silenced in human cancer had been
shown by genetic models (transgene
activation or suppressor gene silencing)
to contribute to neoplasia in mice, we
needed models that recapitulated the
process of epigenetic derangement
itself, in order to determine whether that
mechanism could lead to cancer. My
explanation earned me only a stern fin-
ger waving from Mickey and the oppro-
brious stares of nearby kids, but the
approach was the right one, as illustrated
by an article in this issue from Jaenisch
and colleagues (Holm et al., 2005) show-
ing that loss of imprinting, induced by
hypomethylation in mouse development,
causes cancer. Indeed, much of the can-
cer epigenetics work in mice is from his
group, so I think Mickey should cut him a
break as well.
Genomic imprinting is a parent of ori-
gin-specific relative or complete allelic
silencing, caused by epigenetic modifi-
cations in the gamete or zygote such as
DNA methylation and chromatin modifi-
cation. Loss of imprinting (LOI) in cancer
involves reactivation of the normally
silent allele of a growth-promoting gene,
and/or silencing of the normally active
allele of a tumor suppressor gene. In the
present paper, Holm et al. create a clever
double transgenic stem cell line with a
Cre-inducible Dnmt1 knockout as well as
a Flp-activatable Dnmt1 rescue gene. By
knocking out and then restoring Dnmt1,
they erase imprinting marks, and proba-
bly also nonrecoverable marks in other
genes, but then allow de novo methyla-
tion during embryogenesis. The resulting
mice show loss of imprinting of imprinted
genes generally, including variable acti-
vation of the silent allele of oncogenes
such as Igf2, and silencing of the active
alleles of tumor suppressor genes such
as p57KIP2 and Igf2r. In addition, chimeric
mice develop intestinal adenomas and
hepatocellular cancers. LOI appears to
confer immortalization on cells and
cooperate with Hras in in vitro transfor-
mation experiments (Holm et al., 2005).
The work that got me in hot water
with Mickey also addressed loss of
imprinting in cancer. We and others had
originally described this epigenetic
change in Wilms tumor, an embryonal
tumor common in Beckwith-Wiedemann
syndrome (BWS), and similar changes
are also found in normal cells of Wilms
tumor and BWS patients (reviewed in
Feinberg and Tycko, 2004), indicating
that LOI precedes, and possibly causes,
cancer in these patients. LOI is also com-
mon in adults and associated with both a
positive family history and a personal
history of colorectal neoplasia (Cui et al.,
2003; Woodson et al., 2004). For an epi-
genetic change such as LOI, there is
also the concern that the alteration arose
somehow in association with cancer but
did not play a causal role. We therefore
developed a mouse model, testing the
hypothesis that LOI in combination with
genetic mutation at the gatekeeper gene
Apc in intestinal neoplasia would aug-
ment tumor development, i.e., that LOI
increases the risk of developing cancer
when a mutation occurs, the implication
of the human epidemiological studies.
That was indeed the case, with a 2- to
2.5-fold increased risk of tumors.
Moreover, mice with LOI showed an epi-
genetically induced change in stem cells,
with a shift in the ratio of differentiated to
undifferentiated cells (Sakatani et al.,
2005).
The present study of LOI mice shares
two similarities and one difference with
the previous work. First, both models
appear to involve a disruption of stem
cells that have a delayed effect on tumor
incidence. In the present study, the stem
cell was the direct target of transient
methylation disruption, and in the paper
by Sakatani et al. (2005), tissue-specific
stem cells were found to be affected.
The stem cell is increasingly recognized
as the target for oncogenic alteration,
because it already has many of the prop-
erties that are so vexing in cancer biology
and therapy, such as limited replication
rate, capacity for multilineage differentia-
tion, and even metastasis.
Second, both models of the associ-
ated cancers involve hypomethylation
rather than hypermethylation. While
hypermethylation and/or chromatin modi-
fication is important in tumor suppressor
gene silencing (Jones and Baylin, 2002),
oncogene activation can involve loss of
methylation, and global hypomethylation,
as well as related chromatin alterations,
is a defining attribute of cancer genetics
(Feinberg and Tycko, 2004). Indeed,
three other epigenetic mouse models
from the Jaenisch group support the
causal role of hypomethylation in cancer.
One of these, just published, shows that
hypomethylation induced by a Dnmt1
hypomorphic knockin, and combined with
the Apc mutation (Min mouse), enhances
intestinal neoplasia initiation even though
it retards later gross tumor formation
(Yamada et al., 2005), as shown earlier.
This hypomethylation also cooperates
with Apc to cause liver cancers (Yamada
et al., 2005), a very important result as
liver cancer is the leading cancer killer in
the world. Hypomethylation was also
shown earlier to cause cancer in two
other mouse models from the same
group, aggressive T cell lymphomas in
mice carrying a hypomorphic DNMT1
allele, and accelerated sarcoma forma-
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Epigenetic changes are the most common alterations in human cancer, but it has been difficult to sort out cause and effect
from studies of human tumors. Several recent nonlethal mouse models implicate both hypomethylation and loss of
imprinting (LOI) in tumor formation, including a paper in this issue of Cancer Cell showing that transient hypomethylation
in ES cells causes LOI and liver and intestinal tumors (Holm et al., 2005). Hypomethylation appears to be a critical determi-
nant of cancer, affecting chromosomal stability and specific gene targets.
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tion in mice mutant for p53 and NF1, both
models at least involving increased chro-
mosomal instability caused by the loss of
DNA methylation (Eden et al., 2003;
Gaudet et al., 2003).
Thus, hypomethylation is a critical
determinant of cancer and cancer risk. A
difference between the studies by Holm et
al. and Sakatani et al. is that the present
paper addresses global LOI, demonstrat-
ing that the targets are not limited to IGF2.
Clearly, IGF2 contributes, as its overex-
pression causes a 6-fold increase in focus
formation, but less than that of global LOI.
Of course, other nonimprinted genes that
could not regain methylation may also be
contributing to the cancer phenotype in
the model by Holm et al. One should also
not overlook the important work being
done in mouse knockout models of the
DNA methylation recognition machinery
(Sansom et al., 2003), or knockout of
chromatin modifying genes, such as Snf5,
which causes rhabdoid tumor (Roberts et
al., 2000), or suggestive work involving
Polycomb group members in stem cell
function (Peters et al., 2001; Valk-
Lingbeek et al., 2004).
What studies should follow from
these epigenetic mouse models of can-
cer? First, since we now know that
altered methylation affects cancer risk,
we should ask what are the downstream
effectors and cellular changes that medi-
ate this increased risk? The idea of com-
bining epigenetic with genetic changes
should be developed further, as this is
likely how epigenetic alterations cause
cancer in humans. Second, the models
themselves can be used to test whether
epigenetic changes can be mitigated
therapeutically. This could, but need not,
require pharmacological reversal of epi-
genetic change. One could use agents
already thought to be useful, but not test-
ed in this setting, such as dietary modifi-
cation or nonsteroidal anti-inflammatory
drugs for intestinal tumor risk. Similarly,
drugs that target downstream effectors
of epigenetic change (such as inhibitors
of Igf2 signaling) could be tested. Third,
the approach shown by Holm et al. in
directed methylation changes can be
generalized to tissue-specific modifica-
tions (using tissue-specific Cre, for
example), and to other epigenetic modi-
fiers. Hopefully, studies such as these
will lead to continuing acceptance by the
scientific community of the central role of
epigenetic changes in cancer, and may
even mollify the most critical mouse.
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